

Christophe P.G. Gerald, et al.
Serial No.: Not Yet Known
Filed: Herewith
Page 2

of 37 C.F.R. §§1.821 through 1.825 in connection with this application. Applicants submit herewith twenty seven (27) pages of Sequence Listing, in compliance with the requirements of §§1.821 through 1.825, attached hereto as **Exhibit A**.

Applicants also submit herewith a formatted Sequence Listing in a computer readable form which complies with the requirements of 37 C.F.R. §1.824. In addition, applicants submit a Statement in Accordance with 37 C.F.R. §1.821(f), attached hereto as **Exhibit B**, certifying that the computer readable form containing the nucleic acid and/or amino acid sequences as required by 37 C.F.R. §1.821(e) contains the same information which is submitted as "Sequence Listing".

Information Disclosure Statement

In accordance with their duty of disclosure under 37 C.F.R. § 1.56 and § 1.97 (a)-(b), applicants would like to direct the Examiner's attention to the following references which are listed on the attached Form PTO-1449 (**Exhibit 1**) and which were previously cited in connection with the prosecution of U.S. Serial Numbers 09/405,558, 09/255,368 and 09/161,113 from which the subject application claims benefit under 35 U.S.C. §120. According to 37 C.F.R. §1.98(d), copies of patents or publications that were previously cited by, or submitted to, the Office in connection with such prior applications need not accompany the Information Disclosure Statement. Accordingly, copies of the following references are not attached to this Information Disclosure Statement:

1. PCT International Publication WO 00/00606, published January 6, 2000;

Christophe P.G. Gerald, et al.
Serial No.: Not Yet Known
Filed: Herewith
Page 3

2. European Patent Application EP 0 884 387, published December 16, 1998;
3. Expressed Sequence Tags Database Accession No. AA 449919, published June 4, 1997;
4. Expressed Sequence Tags Database Accession No. AA 449920, published June 4, 1997;
5. Allard, et al., "Mechanisms Underlying the Cardiovascular Responses to Peripheral Administration of NPFF in the Rat", *J. Pharmacol. Exp. Ther.* 274(1): 577-583 (July 1995);
6. Cikoš, et al., "Sequence and Tissue Distribution of a Novel G-Protein-Coupled Receptor Expressed Prominently in Human Placenta," *Biochem. and Biophysical Res. Comm.*, March 16, 1999, 256: 352-356;
7. Devillers, et al., "Characterization of a Potent Agonist for NPFF Receptors: Binding Study on Rat Spinal Cord Membranes" *Neuropharmacology* 33(5): 661-669 (May 1994);
8. Dupouy, et al., "Species Differences in the Localization of Neuropeptide FF Receptors in Rodent and Lagomorph Brain and Spinal Cord" *Peptides* 17(3): 399-405 (1996);
8. Knapp, et al., "Molecular Biology and Pharmacology of Cloned Opioid Receptors" *FASEB J.* 9(7): 516-525 (April 1995); and
9. Payza, et al., "Modulation of Neuropeptide FF Receptors by Guanine Nucleotides and Cations in Membranes of Rat Brain and Spinal Cord" *J. Neurochem.* 60(5): 1894-1899 (May 1993).

Christophe P.G. Gerald, et al.
Serial No.: Not Yet Known
Filed: Herewith
Page 4

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee, other than the \$1,106.00 filing fee enclosed herewith, is deemed necessary in connection with the filing of this Preliminary Amendment and Information Disclosure Statement. However, should any additional fee be necessary, authorization is hereby given to charge such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John E. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400